Objective To study the effect of resveratrol on hepatitis B virus (HBV) and hepatic fibrosis.Methods The rat model of HBV infection was established by intraperitoneal injection of rAAV8-1.3HBV.After successfully establishing the modle, were randomly divided into four groups:negative control group, resveratrol low dose group, high dose group, positive control group, and five rats in each group.Giving a physiological saline, 20 mg/kg respectively resveratrol, 40 mg/kg, 0.1 mg/kg acyclovir via gastrogavage respectively.2、4、8、12 weeks later ,we detected the HBsAg, HBeAg, HBV-DNA via tail vein blooding.HSC-T6 cell model was established.Then rats were divided into two groups, control and resveratrol serum group.Each group was administrated with normal sodium and resveratrol via gastrogavage to make serum.The HSC-T6 viability was observed by AlamarBlue assay.The expression of Col I and TGP-β1 mRNA was determined by Realtime PCR.The expressions of Col I and TGP-β1 Protein was analyzed by WesternBlot.Results Using ELISA method to detect HBsAg、HBeAg、HBV-DNA and found that the expression of HBsAg and HBeAg of negative control group were significantly higher than the rest of the three groups (P<0.05) at the second and the fourth week.The highest expression of HBsAg and HBeAg were (4118 ±367) IU/mL、(160.2 ±56.90) NCU/mL at the second week.The expression of HBV-DNA of negative control group is significantly higher than the rest of the three groups (P<0.05) at the second week.AlamarBlue assay indicated that different concentration of serum of resveratrol can inhibit HSC-T6 proliferation.Compared with control group, serum with drug resveratrol significantly down-regulated the mRNA and protein expression of Col I and TGP-β1.Conclusion Resveratrol inhibits HBV and liver fibrosis by inhibiting type I collagen and TGF-β1.

Objective To investigate the immune response of Adefovir ester combine the Fuzheng Huayu in the process of the treatment of chronic hepatitis B.Methods 100 cases with CHB from March 2010 to October 2014 collected in outpatients clinic or hospital were randomly divided into Adefovir ester treatment group and Adefovir ester joint the Fuzheng Huayu treatment group.Levels of AST, ALT, HBsAg and HBV DNA pre-and-post treatment were detected.CD3-CD56 +,CD244 +NK,CD3 +,CD3 +CD4 +,CD3 +CD8 +T cells and the contents of CD 4 +T cells in serum of two groups were measured by flow cytometry analysis.Results The levels of AST、ALT、HBV-DNA of two group post-treatment were all significantly lower than pre-treatment(P<0.05),and the level of AST and ALT in Adefovir ester and Fuzhengh Huayu treatment group at 3 months and 6 months were obviously lower than Adefovir ester treatment group.HBV-DNA contents between two groups had no significant difference.HbsAg levels of two groups were all significantly increased after 6,9,12 months’treatment (P<0.05),While there was no significant difference between two groups post-treatment.CD3-CD56 +cell at 6,9,12 months in two groups were all higher than pre-treatment(P<0.05), which in Adefovir ester and Fuzhengh Huayu treatment group were more higher than Adefovir ester treatment group(P<0.05).CD244 +NK,CD3 +T cell, CD3 +CD4 +Tcell at each point post-treatment in peripheral blood of two groups were all increased significantly(P<0.05),which in Adefovir ester and Fuzhengh Huayu treatment group increased more obviously than Adefovir ester treatment group (P<0.05).However, CD3 +CD8 +cells were reduced obviously after treatment in two groups(P<0.05), which besides 3 month point, its ratio in Adefovir ester and Fuzhengh Huayu treatment group decreased more significantly than Adefovir ester treatment group at other points( P<0.05 ).Cytokines in serum of two groups were all increased significantly post-treatment ( P<0.05 ) , which in Adefovir ester and Fuzhengh Huayu treatment group were more lower (P<0.05).Conclusion Adefovir ester and Fuzhengh Huayu treatment can improve the situation of AST, ALT, HBV DNA and HBsAg in patients with chronic hepatitis B,promote the expression of NK cells,T cells and Tcell secrited cytokines,and the efficacy is better than Adefovir estertreatment alone.

Objective To understand the progress of paclitaxel carriers, to provide theoretical support for research of paclitaxel carriers and clinical use of paclitaxel.Methods To study literatures on paclitaxel carriers recently and understand the research direction of paclitaxel carriers.Subsequently, the advantages and disadvantages of various paclitaxel carriers were analyzed and summarized.Results Paclitaxel as an effective anti-tumor chemotherapy drugs, had poorly water-soluble, serious toxicity and side effects, which limited the wide application of paclitaxel to some degree.Development of liposomes, micelles, microspheres, nanoparticles and other new dosage forms had broken these restrictions, which had vital significance.Conclusion Paclitaxel carriers can improve the solubility of the drug, reduce side effects, and develop toward multi-functional and finely targeted.

OBJECTIVE:To provide a reference for clinical use of anti-tumor adjuvant drugs as is reasonable,effective and economical. METHODS:By retrospective investigation and analysis,the utilization of anti-tumor adjuvant drugs in the oncology department of our hospital during 2010 and 2013 was analyzed statistically in respect of the type,dosage form,consumption amount,DDDs,DDC,DUI etc. RESULTS:The anti-tumor adjuvant drugs in our hospital were dominated by injections,especial-ly domestic drugs,the consumption amount of which accounted for 80% of the total consumption amount of anti-tumor adjuvant drugs each year. The anti-tumor adjuvant drugs were mainly used for symptomatic treatment of various adverse reactions. Drug syn-chronization was relatively good each year,however,excessive use of individual drugs existed. CONCLUSIONS:Anti-tumor adju-vant drugs have relatively better synchronism in the drugs quantities and medication number. However,individual drugs have exces-sive use and other irrational use.

Lurasidone is a new atypical antipsychotic drug, it was approved by the Food and Drug Administration ( FDA ) for treatment of schizophrenia on october 28,2010.The article is to provide an review about pharmacological effects, clinical applications, pharmacokinetics, dosage, drug interactions, adverse reactions of Lurasidone.

OBJECTIVE:To provide reference for solving the shortage of national essential medicines in Changchun. METH-ODS:According to preliminary work,a questionnaire was conducted to investigate and statistically analyze the shortage situation of essential medicines in 22 higher than secondary and 50 basic medical and health institutions in Changchun;ABC analysis was used to analyze the national essential medicines in shortage;the bid results and shortage causes of the primary and secondary nation-al essential medicines in shortage were inquired. RESULTS:Totally 72 questionnaire were send out,and 72 were recycled with ef-fective recovery of 100%. The investigation results showed there were 19 shortage breeds(22 dosage forms),which lost the bid-ding,and 99 breeds(111 dosage forms)of national essential medicines in shortage,which won the bidding,including 85 kinds of chemical medicines and biological products,14 kinds of Chinese patent medicine in Changchun. Cardiovascular system drugs shows the largest number in the bid chemical medicines and biological products,and the Chinese patent medicine were mainly Fu-zheng agent and Quyu agent(internal medicine). Results of ABC analysis showed,among the 111 bid shortage dosage forms,17 were primary and 23 were secondary. The main causes for them were price raising in raw materials,lack of production,no produc-ing in manufacturers and purchase price higher than winning bids. CONCLUSIONS:Low accessibility of raw material drugs,low enthusiasm to production,lower drug price than a reasonable level,and small clinical requirements can lead to the shortage of na-tional essential medicines. It is suggested to intensify in supervising the raw materials’marketing,raising the enthusiasm of manu-facturers,perfecting the system of drug bidding,developing fixed-point production and building drug reserve system to guarantee the production and supply of national essential medicines,and satisfy clinical demands.

Objective To investigate the extracting technology of the Northeast tussah pupa oil and analyze the composition of the oil. Methods The Northeast tussah pupa were crushed and dried at 60℃. The oil was extracted from the Northeast tussah pupa powder with super critical fluid extraction technology-CO2 (SFE-CO2) at the extracting temperature as 45 ℃,pressure as 50 MPa and operating time as 6 hours according to the results of homogeneous design. The composition of the oil was detected by gas chromatography (GC).Results The extracting rate of the oil from the Northeast tussah pupa powder was 17.93% (w/w)and the percent of compositions of the oil were C15:0 fatty acid 37.03%,hexadecanoic acid 5.63%,C17:0 fatty acid 32.81%,octadecanoic acid 1.79%,leic acid 3.75%,octadecadienoic acid 11.98% and α-1inoleic acid 7.00%. Conclusion The technology of SFE-CO2 can be used in extraction of Northeast tussah pupa with High extraction efficiency.

A large number of literatures at home and abroad in recent years about Schisandrin B were viewed and its pharmacological effects were summarized. Schisandrin B has a variety of pharmacological activities, which can reduce transaminase activity in liver cells, inhibit lipid peroxidation, anti-oxidant, hepatoprotection, anti-tumor and so on. Its pharmacological effects are accurate and worthy of research and development as a potential drug.

OBJECTIVE:To provide reference for promoting rational use of vancomycin in the clinic. METHODS:Referring to vancomycin instruction,Guiding Principles for Clinical Use of Antibacterials (2015 edition) and Chinese Expert Consensus on Clinical Use of Vancomycin (2011 edition),720 inpatient medical records of vancomycin were collected from our hospital during Jan. 2013-Dec. 2014,and then drug use of those inpatients were analyzed retrospectively. RESULTS:Among 720 cases,male (428 cases)was more than female(292 cases),and most of them aged 41-65(45.83%). There were 50 cases of prophylactic drug use(6.94%)and 670 cases of therapeutic drug use(93.06%). The patients came from 36 departments. Among 720 cases,the dose of 19 cases were higher than 2 g/d,and there were 13 ADR cases(1.81%). Among 670 cases of therapeutic drug use,587 cases of microbiological samples (87.61%) were detected,and other antibacterials were used in 522 cases additionally (77.91%). DUI of vancomycin was equal to 0.96 in 549 cases no younger than 18 years old of herapeutic drug use. There were 240 cases of unsuit-able drug use (33.33%) in total,including 192 cases of unsuitable solvent (26.67%),28 cases of unsuitable usage and dosage (3.89%)and 20 cases of unsuitable drug combination(2.78%). CONCLUSIONS:The use of vancomycin in our hospital is basi-cally rational;vancomycin is widely used in departments;drug combination is a common phenomenon;the inspection rate of mi-crobiological samples is qualified;no drug abuse is found. However,there still is inappropriate use in the clinic. It is recommended to strengthen special evaluation and training about rational use of vancomycin,and further standardize monitoring for vancomycin use so as to guarantee the safety of drug use.

Objective To prepare pemirolast potassium nasal spray which could be used in treatment of allergic rhinitis and make a quality control standard for the preparation.Methods The preparation materials of nasal spray was selected which could meet the physical and chemical properties of pemirolast potassium as well as the characteristics of intranasal administration.The quality control standards for pemirolast potassium nasal spray was made according to the nasal spray quality standards for the formulation pH, property, loading capacity, total bottle spray times, puff volume, sedimentation volume ratio and detection of content of “Chinese Pharmacopoeia” two section (2010 edition).Results The formulation prescription of pemirolast potassium nasal spray was:0.1% potassium pemirolast, 0.8% CMC-Na, 0.01% benzalkonium bromide, glacial acetic acid ( pH adjusting agent) and the solution was 5% mannitol.The formulation was a white suspension, pH=7.The mean value of installed capacity was (25.12 ±0.16) mL and installed capacity of each bottle was above 23.75 mL(95%); total spray times of each bottle was above 160 sprays and spray volume was above 0.140 0 g/press; sedimentation volume ratio was 1, the above testing programmes of quality standard met the requirements and were controlled.The standard curve of pemirolast potassium reference substance was Y=81085X+15264(r=0.999 8), linearity range was 0.5~25.0μg/mL.The average recovery rate of pemirolast potassium sample was 99.39%, and precision met the requirements.The pemirolast potassium content of test sample was 99.2% of labeled amount.Conclusion The formulation prescription of pemirolast potassium nasal spray is suitable and the preparation is possessed several advantages such as stability, well-distributed spray, application convenience and quality controlled.Therefore, nasal administrated formulation of pemirolast potassium is potentially in further.